Angiogenesis is a significant event in a wide range of healthy and diseased conditions. This
process frequently involves vasodilation and an increase in vascular permeability …

Tumours require a vascular supply to grow and can achieve this via the expression of pro-
angiogenic growth factors, including members of the vascular endothelial growth factor …

Purpose To provide recommendations on the appropriate use of breast tumor biomarker
assay results to guide decisions on systemic therapy for metastatic breast cancer. Methods A …

When the VEGF-A-targeting monoclonal antibody bevacizumab (Avastin®) entered clinical
practice more than 15 years ago, it was one of the first targeted therapies and the first …

Background The addition of bevacizumab to chemotherapy improves progression-free
survival in metastatic breast cancer and pathological complete response rates in the …

Simple Summary Several anti-angiogenic drugs have been approved for cancer treatment,
alone or in combination with other anti-tumoral agents. Angiogenesis inhibitors cause drug …

Background Bevacizumab has consistently demonstrated improved progression-free
survival (PFS) and response rate when combined with first-line chemotherapy for HER2 …

The humanized monoclonal antibody bevacizumab (Avastin®) has been available in the EU
since 2005. Results of phase III trials demonstrate that adding intravenous bevacizumab to …

Angiogenesis is a process of neovascular formation from pre-existing blood vessels, which
consists of sequential steps for vascular destabilization, angiogenic sprouting, lumen …

Angiogenesis is one of the hallmarks of cancer and a crucial requisite in the development of
tumors. Interrupting this process by blocking the vascular endothelial growth factor (VEGF) …